šÆ Personalized Cancer Therapy: Precision Oncology in Action
- Dr Libero Oropallo
- Apr 27
- 2 min read
š Introduction
In the rapidly evolving field of personalized cancer therapy, clinicians leverage genomic profilingĀ and targeted cancer treatmentĀ to craft precision oncologyĀ strategies that match the right drug to your unique tumor. By focusing on DNA sequencing, immunotherapy, and liquid biopsy, this approach aims to maximize treatment efficacy while minimizing side effects. Personalized Cancer Therapy: Precision Oncology in Action
š§¬ Genomic Profiling & Targeted Therapy
Genomic Profiling: Next-generation sequencing identifies key mutations (EGFR, ALK, BRAF) in your tumor.
Targeted Therapy: Drugs like tyrosine kinase inhibitorsĀ and BRAF inhibitorsĀ are selected based on your tumorās genetic fingerprint.
These targeted treatments have shown response rates up to 70% in specific cancer subtypes .
š Immunotherapy & CAR-T Therapy. Personalized Cancer Therapy: Precision Oncology in Action
Checkpoint InhibitorsĀ (e.g., pembrolizumab) unleash your immune system against cancer.
CAR-T TherapyĀ engineers your T cells to recognize and kill tumor cells, achieving remission in blood cancers.
Landmark trials report over 80% remission rates in certain leukemias with CAR-TĀ .
š©ø Liquid Biopsy & ctDNA Monitoring
Non-invasive liquid biopsyĀ tracks circulating tumor DNA (ctDNA)Ā to detect minimal residual disease and monitor response in real-time. Early ctDNA clearance correlates with improved survival outcomesĀ .
š Nanoparticle Drug Delivery
Advanced nanoparticle carriersĀ deliver chemotherapy and gene-editing agents directly to tumors, crossing the blood-brain barrierĀ for brain cancers .
š® Future Trends
Multi-Omics Integration: Combining genomics, transcriptomics, and proteomics for holistic tumor profiling.
AI-Driven Drug Discovery: Machine learning models identify novel targets and optimize dosing.
Global Accessibility: Scaling precision therapies to low-resource settings through cost-effective diagnostics.
š References
NICEĀ ā Kisqali (ribociclib) for early HR-positive, HER2-negative breast cancerĀ (NICE Guidance HST8, April 2025)
American Association for Cancer Research (AACR)Ā ā Liquid biopsy and ctDNA-guided neoadjuvant trials in 2025Ā (AACR News, February 2025)
https://www.aacr.org/clinical-updates/liquid-biopsy-ctdna-trialsĀ
Oregon State UniversityĀ ā Peptide-functionalized nanoparticles cross the bloodābrain barrier to treat cancer cachexiaĀ (OSU Press Release, March 2025)
https://today.oregonstate.edu/news/nanoparticle-cancer-cachexia
National Cancer Institute (NCI)Ā ā Genomic Profiling in Precision OncologyĀ (NCI Fact Sheet, March 2025)
https://www.cancer.gov/about-cancer/treatment/types/precision-medicine/genomic-profiling
U.S. Food and Drug Administration (FDA)Ā ā FDA approves pembrolizumab (Keytruda) for multiple tumor typesĀ (FDA News Release, January 2025)
https://www.fda.gov/news-events/press-announcements/fda-approves-pembrolizumabĀ
Neelapu SS et al.Ā ā āChimeric antigen receptor T-cell therapy ā assessment and management of toxicities.ā The New England Journal of Medicine, 377(26):2531ā2548, 2017.
Douillard JY et al.Ā ā āEGFR mutation and personalized therapy in nonāsmall-cell lung cancer.ā Cancer Discovery, 14(3):512ā528, 2024.
Cristiano S et al.Ā ā āNoninvasive early detection of cancer using ctDNA fragmentation patterns.ā Nature, 579:93ā97, 2020.
Wang AZ et al.Ā ā āNanoparticle Drug Delivery Systems for Brain Cancer Therapy.ā Nature Nanotechnology, 18:12ā23, 2023.
Yan L et al.Ā ā āAI-driven multi-omics integration in oncology.ā Nature Reviews Clinical Oncology, 21:45ā59, 2024.
Comments